Aridis Pharmaceuticals announced that the Food and Drug Administration (FDA) granted Fast Track designation to AR-301 for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA).
AR-301 is currently in a Phase 2a, randomized, double-blind, placebo-controlled clinical trial comparing the safety and efficacy of AR-301 as adjunctive therapy with standard-of-care antibiotics vs. antibiotics alone in HAP and VAP patients. AR-301 is designed to be effective on bacterial infections regardless of conventional antibiotics’ resistance patterns.
AR-301 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Gram-positive Staphylococcus aureus bacteria, including MRSA.
For more information call (408) 385–1742 or visit AridisPharma.com.